Literature DB >> 16857665

Fluorescent indicators distributed throughout the pharmacophore of cholecystokinin provide insights into distinct modes of binding and activation of type A and B cholecystokinin receptors.

Kaleeckal G Harikumar1, Delia I Pinon, Laurence J Miller.   

Abstract

Ligand probes with fluorescent indicators positioned throughout the pharmacophoric domain can provide important insights into the molecular basis of receptor binding and activation as reflected in the microenvironment of each indicator while docked at a receptor. We developed three cholecystokinin-like probes with Aladan situated at the N terminus, in the mid-region, and at the C terminus (positions 24, 29, and 33, respectively). These were studied in solution and docked at type A and B cholecystokinin receptors. This study demonstrated clear differences in mechanisms of cholecystokinin binding and activation of these structurally related receptors with distinct agonist structure-activity relationships. The fluorescence characteristics of Aladan are highly sensitive to the polarity of its microenvironment. The mid-region probe was least accessible to the aqueous milieu as determined by fluorescence emission spectra and iodide quenching, which was not altered by changes in conformation from active to inactive. Accessibility of the N- and C-terminal probes was affected by receptor conformation. The position 24 probe was more easily quenched in the active than in the G protein-uncoupled conformation for both receptors. However, the position 33 probe docked at the type A cholecystokinin receptor was more easily quenched in the active conformation, whereas the same probe docked at the type B cholecystokinin receptor was more easily quenched in the inactive conformation. Fluorescence anisotropy and red edge excitation shift determinations confirmed these observations and supported the proposed movements. Although both type A and B cholecystokinin receptors bind cholecystokinin with high affinity, resulting in fully efficacious biological responses, these receptors utilize distinct molecular modes of binding.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16857665     DOI: 10.1074/jbc.M605098200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  Differential sensitivity of types 1 and 2 cholecystokinin receptors to membrane cholesterol.

Authors:  Ross M Potter; Kaleeckal G Harikumar; S Vincent Wu; Laurence J Miller
Journal:  J Lipid Res       Date:  2011-10-21       Impact factor: 5.922

2.  Elimination of a cholecystokinin receptor agonist 'trigger' in an effort to develop positive allosteric modulators without intrinsic agonist activity.

Authors:  Aditya J Desai; Brad R Henke; Laurence J Miller
Journal:  Bioorg Med Chem Lett       Date:  2015-03-24       Impact factor: 2.823

3.  Molecular basis for binding and subtype selectivity of 1,4-benzodiazepine antagonist ligands of the cholecystokinin receptor.

Authors:  Erin E Cawston; Polo C H Lam; Kaleeckal G Harikumar; Maoqing Dong; Alicja M Ball; Mary Lou Augustine; Eyup Akgün; Philip S Portoghese; Andrew Orry; Ruben Abagyan; Patrick M Sexton; Laurence J Miller
Journal:  J Biol Chem       Date:  2012-03-30       Impact factor: 5.157

4.  Elucidation of the molecular basis of cholecystokinin Peptide docking to its receptor using site-specific intrinsic photoaffinity labeling and molecular modeling.

Authors:  Maoqing Dong; Polo C-H Lam; Delia I Pinon; Ruben Abagyan; Laurence J Miller
Journal:  Biochemistry       Date:  2009-06-16       Impact factor: 3.162

5.  Molecular Mechanism of Action of Triazolobenzodiazepinone Agonists of the Type 1 Cholecystokinin Receptor. Possible Cooperativity across the Receptor Homodimeric Complex.

Authors:  Aditya J Desai; Polo C H Lam; Andrew Orry; Ruben Abagyan; Arthur Christopoulos; Patrick M Sexton; Laurence J Miller
Journal:  J Med Chem       Date:  2015-12-10       Impact factor: 7.446

6.  Use of multidimensional fluorescence resonance energy transfer to establish the orientation of cholecystokinin docked at the type A cholecystokinin receptor.

Authors:  Kaleeckal G Harikumar; Fan Gao; Delia I Pinon; Laurence J Miller
Journal:  Biochemistry       Date:  2008-08-13       Impact factor: 3.162

7.  Direct demonstration of unique mode of natural peptide binding to the type 2 cholecystokinin receptor using photoaffinity labeling.

Authors:  Maoqing Dong; Laurence J Miller
Journal:  Peptides       Date:  2013-06-14       Impact factor: 3.750

8.  A type 1 cholecystokinin receptor mutant that mimics the dysfunction observed for wild type receptor in a high cholesterol environment.

Authors:  Aditya J Desai; Kaleeckal G Harikumar; Laurence J Miller
Journal:  J Biol Chem       Date:  2014-05-13       Impact factor: 5.157

9.  Membrane cholesterol affects stimulus-activity coupling in type 1, but not type 2, CCK receptors: use of cell lines with elevated cholesterol.

Authors:  Kaleeckal G Harikumar; Ross M Potter; Achyut Patil; Valerie Echeveste; Laurence J Miller
Journal:  Lipids       Date:  2013-01-11       Impact factor: 1.880

Review 10.  Structural basis of cholecystokinin receptor binding and regulation.

Authors:  Laurence J Miller; Fan Gao
Journal:  Pharmacol Ther       Date:  2008-05-11       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.